516 related articles for article (PubMed ID: 21228029)
1. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
[TBL] [Abstract][Full Text] [Related]
2. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
[TBL] [Abstract][Full Text] [Related]
4. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A
Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971
[TBL] [Abstract][Full Text] [Related]
6. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
[TBL] [Abstract][Full Text] [Related]
7. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
Sipe JC
Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
[TBL] [Abstract][Full Text] [Related]
8. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
11. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
[TBL] [Abstract][Full Text] [Related]
12. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
Hermann R; Litwin JS; Friberg LE; Dangond F; Munafo A
Br J Clin Pharmacol; 2019 Jul; 85(7):1484-1494. PubMed ID: 30883839
[TBL] [Abstract][Full Text] [Related]
13. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
15. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
[TBL] [Abstract][Full Text] [Related]
16. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
18. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
19. Cladribine tablets: in relapsing-remitting multiple sclerosis.
Muir VJ; Plosker GL
CNS Drugs; 2011 Mar; 25(3):239-49. PubMed ID: 21323395
[TBL] [Abstract][Full Text] [Related]
20. Cladribine: mode of action and implications for treatment of multiple sclerosis.
Leist TP; Weissert R
Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]